Company intelligence / Profile preview

OnkosXcel Therapeutics

New Haven, Connecticut, USAbioxceltherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BXCL701 in combination with pembrolizumab (Keytruda) showed a composite response rate of 25% in small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC) with a favorable safety profile. This compares favorably to the 2-5% response rate seen with Keytruda alone in this patient population[4].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

BXCL701

Phase 2

Indications: Metastatic castration-resistant prostate cancer, Pancreatic cancer, Acute myelogenous leukemia, Melanoma, Soft tissue sarcoma

Partnerships

Merck & Co.

Beyond the preview

Go deeper on OnkosXcel Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OnkosXcel Therapeutics.

Explore the full profile